The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

NCT06217185 PHASE4 RECRUITING

This is a multi-center real-world study, in which patients who meet the inclusion criteria will receive treatment with Pyrotinib + Trastuzumab + Taxanes. Taxanes will be used for 6-8 cycles or discontinued due to intolerable Adverse Events (AEs), after which Capecitabine will be used for rhythmic chemotherapy combined with Pyrotinib + Trastuzumab. The aim is to explore the efficacy and safety of Pyrotinib, Trastuzumab, and Taxanes in treating Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

Details

Lead sponsor	Hebei Medical University Fourth Hospital
Phase	PHASE4
Status	RECRUITING
Enrolment	100
Start date	Tue Jan 02 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Jun 30 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• HER2-positive Breast Cancer
• Advanced Breast Cancer

Interventions

• Pyrotinib
• Trastuzumab
• Taxanes
• Capecitabine

Countries

China